On September 8, AstraZeneca (UK) suspended the clinical trial of its coronavirus vaccine due to the suspected side effects of a new coronavirus vaccine and an unexplained illness in a volunteer during the clinical trial.
AstraZeneca’s public relations department said that the clinical trial of the vaccine will be stopped automatically in order to allow an independent committee to investigate the safety data.
AstraZeneca’s public relations department said that the suspension was a measure to ensure the complete safety of the trial when the possibility of unexplained symptoms in the clinical trial was discovered, and that an investigation was underway.
AZD1222, a vaccine jointly developed by Oxford University and AstraZeneca, has been temporarily suspended from clinical trials. According to AstraZeneca, after vaccination with this vaccine, serious side effects are suspected to occur among participants in clinical trials.
Japanese Minister of Health, Labor and Welfare Katsunobu Kato said on August 7 that the Japanese government has basically reached an agreement with British pharmaceutical giant AstraZeneca on the supply of 120 million doses of the new coronavirus infection vaccine to be developed by the company, if the vaccine is put into practice, starting next year.
Japan originally planned to receive 30 million doses by the end of March next year. Kato told the media, “We will rapidly move forward with discussions toward a final contract, and will continue discussions with other vaccine manufacturers.” At that time, the Japanese government had almost reached an agreement with U.S. pharmaceutical giant Pfizer on accepting a supply of 60 million doses of vaccine.
Japan has just begun clinical trials of the vaccine since late last month, and AstraZeneca says that clinical trials have been suspended, including in Japan, to test its safety.
Recent Comments